Abstract 7P
Background
Neutrophil extracellular traps (NETs) are involved in the progression and metastasis of a variety of malignancies. Our previous studies have confirmed that tumor cell-released autophagosomes (TRAPs) induced immunosuppression TME formation. However, it remains to be investigated whether TRAPs-treated neutrophils contribute to the metastatic colonization of the lungs by tumor cells.
Methods
NETs were observed by scanning electron microscopy (SEM) and Confocal Microscope. Western blot and ELISA were used to quantify MPO-DNA, NE, and cit-H3 which are important components of NETs. In vivo, TRAPs were injected into the tail vein of mice and Beclin1 knockdown 4T1 tumor cells engineering to reduce TRAPs release were injected into mice subcutaneously. The characteristic molecules of NETs in plasma were detected. The study used antibody blocking assays and HMGB1 knockdown cell lines to identify key DAMPs on the surface of TRAPs. Inhibitor-treated neutrophils and TLR4 knockout mice were used to identify functional receptors on neutrophils. Flow cytometry was used to evaluate the effect of TRAPs on T cell function and lung infiltrating T cell function, as well as to monitor late lung metastases in neutrophils treated with TRAPs suppressor.
Results
Numerous reticular structures significantly increased in the cell culture supernatant after TRAPs treatment. In vivo, NETs were significantly increased in plasma after tail vein injection of TRAPs as well as in 4T1 tumor-bearing mice. Conversely, NETs were significantly decreased in the plasma of Beclin1 knockdown 4T1 tumor-bearing mice. TRAPs derived from breast tumor cell lines induced neutrophil formation of NETs via the HMGB1-TLR4-MyD88-ERK/p38 pathway. This process inhibited the proliferation and secretion of IFN-γ in CD4+ and CD8+ T cells, ultimately leading to increased lung metastasis.
Conclusions
Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation. Overall, these findings define a novel mechanism mediated by TRAPs in neutrophils, which may suppress anti-tumor T cell immunity and highlight TRAPs as an important target for future tumor immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
C. Wu, X. Wang.
Funding
Supported by National Natural Science Foundation of China.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract